HC Wainwright reissued their neutral rating on shares of Agenus (NASDAQ:AGEN – Free Report) in a report released on Friday,Benzinga reports. The brokerage currently has a $7.00 price target on the biotechnology company’s stock.
Several other equities research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley cut their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.
Get Our Latest Report on Agenus
Agenus Trading Down 2.0 %
Institutional Investors Weigh In On Agenus
Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after acquiring an additional 4,134,232 shares during the period. Walleye Capital LLC bought a new position in shares of Agenus during the third quarter worth approximately $1,003,000. Price T Rowe Associates Inc. MD raised its position in shares of Agenus by 52.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Agenus in the second quarter valued at approximately $1,921,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Agenus during the second quarter worth approximately $1,050,000. Institutional investors and hedge funds own 61.46% of the company’s stock.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Articles
- Five stocks we like better than Agenus
- Best Aerospace Stocks Investing
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Penny Stocks Ready to Break Out in 2025
- What Does a Stock Split Mean?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.